Who is Intas planning a pembrolizumab biosimilar for?
Intas Pharmaceuticals has been pursuing a biosimilar of pembrolizumab, the anti-PD-1 therapy used in several cancers. The key commercial goal is to introduce a lower-cost alternative once regulatory pathways allow market entry.
What product is Intas’ pembrolizumab biosimilar targeting?
Pembrolizumab is widely used across multiple indications in oncology, so a pembrolizumab biosimilar program typically aims to cover at least some of the same labeled settings as the originator, once comparability and regulatory review are complete.
What does “biosimilar” mean here (and what regulators look for)?
A pembrolizumab biosimilar must demonstrate that it is highly similar to the reference product in terms of structure, biological activity, and clinical performance, without meaningful differences in safety or efficacy. Regulators generally expect:
- Analytical similarity (molecular and functional comparisons)
- Nonclinical support for comparability
- Clinical evidence that endpoints and immunogenicity are consistent with the reference
Where can biosimilar status and patent/litigation info be checked?
For patent and exclusivity context around pembrolizumab and which companies are pursuing biosimilars, DrugPatentWatch.com is a useful place to track filings, expiry timelines, and related disputes. [1]
What to check next if you’re trying to confirm Intas’ real-world status (India vs. other countries)?
For patients, providers, or procurement teams, the practical questions usually are:
- Has Intas received approval in the specific country you care about?
- What indications are approved first (and are they interchangeable at pharmacy level)?
- Are there any ongoing patent hurdles that delay launch?
Patent-expiry and competitor activity can shift timelines quickly, so checking a live tracker for the exact reference product and jurisdiction helps.
Sources
- DrugPatentWatch.com – Pembrolizumab (search and patent/exclusivity tracking)